PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs INCY |
|---|---|---|---|---|---|
| EXEL | Exelixis, Inc. | 0.34 | 17.8 | 51.6% | +37% |
| HALO | Halozyme Therapeutics, Inc. | 0.88 | 19.9 | 22.7% | +249% |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.50 | 19.9 | 5.7% | +1295% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.67 | 30.0 | 8.2% | +1364% |
| BMRN | BioMarin Pharmaceutical Inc. | 5.62 | 151.3 | 26.9% | +2139% |